Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Me-Too" Drug Pediatric Study Should Await Safety Data From Marketing

Executive Summary

"Me-too" drugs could be required to include statements recommending use of competitor drugs as part of the "pediatric use" section of labeling, FDA's final pediatric rule indicates.
Advertisement

Related Content

Pediatric Waivers Contingent On Study Attempts In Sub-Populations - FDA
Pediatric Waivers Contingent On Study Attempts In Sub-Populations - FDA
Advertisement
UsernamePublicRestriction

Register

PS033258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel